Gilead nabs Chinese nod for Sovaldi, eyeing world's largest hepatitis C patient base

25th September 2017 Uncategorised 0

After uptake of Sovaldi and Harvoni waned and fierce competition emerged in the U.S., Gilead Sciences has gained a foothold in China—the world’s largest hepatitis C market—with an approval for Sovaldi from China’s FDA.

More: Gilead nabs Chinese nod for Sovaldi, eyeing world's largest hepatitis C patient base
Source: fierce